{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:52:45Z","timestamp":1785851565768,"version":"3.56.0"},"reference-count":222,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPG\/2020\/971"],"award-info":[{"award-number":["GOIPG\/2020\/971"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.addr.2022.114342","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T03:30:12Z","timestamp":1652412612000},"page":"114342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies"],"prefix":"10.1016","volume":"187","author":[{"given":"Rasha A.","family":"Alshaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Waeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114342_b0005","article-title":"World report on vision","author":"Who","year":"2019","journal-title":"Geneva: World Health Organization"},{"key":"10.1016\/j.addr.2022.114342_b0010","doi-asserted-by":"crossref","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study, Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study, The Lancet Global Health. 9 (2021) e144\u2013e160. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7.","DOI":"10.1016\/S2214-109X(20)30489-7"},{"key":"10.1016\/j.addr.2022.114342_b0015","doi-asserted-by":"crossref","unstructured":"S.R. Flaxman, R.R.A. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite, M.V. Cicinelli, A. Das, J.B. Jonas, J. Keeffe, J.H. Kempen, J. Leasher, H. Limburg, K. Naidoo, K. Pesudovs, A. Silvester, G.A. Stevens, N. Tahhan, T.Y. Wong, H.R. Taylor, R. Vision Loss Expert Group of the Global Burden of Disease Study, Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis, The Lancet Global Health. 5 (2017) e1221\u2013e1234. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5.","DOI":"10.1016\/S2214-109X(17)30393-5"},{"issue":"3","key":"10.1016\/j.addr.2022.114342_b0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0025","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1167\/iovs.10-6768","article-title":"Beyond AREDS: Is There a Place for Antioxidant Therapy in the Prevention\/Treatment of Eye Disease?","volume":"52","author":"Kowluru","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581288","article-title":"Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane\/Human Vitreous Platform","volume":"11","author":"Rezzola","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2022.114342_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","article-title":"Treatment of diabetic retinopathy: Recent advances and unresolved challenges","volume":"7","author":"Stewart","year":"2016","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.addr.2022.114342_b0045","first-page":"851","article-title":"Recent Developments in the Treatment of Wet Age-related Macular Degeneration, Curr","volume":"40","author":"Papadopoulos","year":"2020","journal-title":"Med Sci."},{"key":"10.1016\/j.addr.2022.114342_b0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0055","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.addr.2022.114342_b0060","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114342_b0065","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114342_b0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00417-011-1851-1","article-title":"Endophthalmitis following intravitreal injections","volume":"250","author":"Irigoyen","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","article-title":"Complications of intravitreal injections","volume":"21","author":"Sampat","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0080","series-title":"Ocular Transporters and Receptors","first-page":"1","author":"Cholkar","year":"2013"},{"key":"10.1016\/j.addr.2022.114342_b0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114342_b0090","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.drudis.2019.05.032","article-title":"The safety evaluation of long-acting ocular delivery systems","volume":"24","author":"Thackaberry","year":"2019","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.addr.2022.114342_b0095","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.ico.0000240084.27663.fd","article-title":"Corneal Toxicity From Topical Ocular and Systemic Medications","volume":"25","author":"Fraunfelder","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114342_b0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4155\/tde-2017-0097","article-title":"Posterior drug delivery via periocular route: challenges and opportunities","volume":"8","author":"Waite","year":"2017","journal-title":"Ther Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0110","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0002-9394(00)00501-8","article-title":"Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis","volume":"130","author":"Ozerdem","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jop.2007.0117","article-title":"Pharmacokinetic Study of Dexamethasone Disodium Phosphate using Intravitreal, Subconjunctival, and Intravenous Delivery Routes in Rabbits","volume":"24","author":"Hosseini","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114342_b0120","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/IAE.0b013e3182576d1d","article-title":"Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits","volume":"32","author":"Wang","year":"2012","journal-title":"Retina."},{"key":"10.1016\/j.addr.2022.114342_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","article-title":"Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments","volume":"11","author":"Rimpel\u00e4","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye."},{"issue":"10","key":"10.1016\/j.addr.2022.114342_b0135","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.bbamem.2016.02.020","article-title":"Tear film lipid layer: A molecular level view","volume":"1858","author":"Cwiklik","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes."},{"key":"10.1016\/j.addr.2022.114342_b0140","first-page":"735","article-title":"A COMPREHENSIVE INSIGHT ON OCULAR PHARMACOKINETICS, Drug Deliv","volume":"6","author":"Agrahari","year":"2016","journal-title":"Transl Res."},{"key":"10.1016\/j.addr.2022.114342_b0145","first-page":"171","article-title":"Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations","volume":"63","author":"Loftsson","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.addr.2022.114342_b0150","series-title":"Encyclopedia of the Eye","first-page":"42","article-title":"Drug Delivery to Cornea and Conjunctiva: Esterase- and Protease-Directed Prodrug Design","author":"Talluri","year":"2010"},{"key":"10.1016\/j.addr.2022.114342_b0155","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114342_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jop.1997.13.41","article-title":"Penetration into the Anterior Chamber Via the Conjunctival\/Scleral Pathway","volume":"13","author":"Schoenwald","year":"1997","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114342_b0165","doi-asserted-by":"crossref","unstructured":"D.M. Maurice, S. Mishima, Ocular Pharmacokinetics, in: M.L. Sears (Ed.), Pharmacology of the Eye, Springer, Berlin, Heidelberg, 1984: pp. 19\u2013116. https:\/\/doi.org\/10.1007\/978-3-642-69222-2_2.","DOI":"10.1007\/978-3-642-69222-2_2"},{"key":"10.1016\/j.addr.2022.114342_b0170","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1124\/dmd.116.069369","article-title":"Drug Transport by the Blood-Aqueous Humor Barrier of the Eye","volume":"44","author":"Lee","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2022.114342_b0175","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.addr.2022.114342_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/601731","article-title":"An Update on Ocular Surface Epithelial Stem Cells: Cornea and Conjunctiva","volume":"2015","author":"Ramos","year":"2015","journal-title":"Stem Cells International."},{"key":"10.1016\/j.addr.2022.114342_b0185","first-page":"66","article-title":"OCULAR LYMPHATICS: STATE-OF-THE-ART REVIEW","volume":"42","author":"Chen","year":"2009","journal-title":"Lymphology."},{"key":"10.1016\/j.addr.2022.114342_b0190","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11095-007-9408-z","article-title":"Drug Elimination Kinetics Following Subconjunctival Injection Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging","volume":"25","author":"Kim","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1211\/jpp.57.12.0005","article-title":"Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration","volume":"57","author":"Amrite","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114342_b0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0014-4835(03)00212-4","article-title":"Scleral structure, organisation and disease","volume":"78","author":"Watson","year":"2004","journal-title":"A review, Exp Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0205","doi-asserted-by":"crossref","first-page":"0410061","DOI":"10.1115\/1.4029430","article-title":"Collagen Structure and Mechanical Properties of the Human Sclera: Analysis for the Effects of Age","volume":"137","author":"Coudrillier","year":"2015","journal-title":"J. Biomech. Eng."},{"key":"10.1016\/j.addr.2022.114342_b0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.addr.2022.114342_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108187","article-title":"Potential of subconjunctival aflibercept in treating choroidal neovascularization","volume":"199","author":"Nirmal","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0225","doi-asserted-by":"crossref","unstructured":"C.J. Zeiss, D.C. Tu, I. Phan, R. Wong, P.M. Treuting, 21 - Special Senses: Eye, in: P.M. Treuting, S.M. Dintzis, K.S. Montine (Eds.), Comparative Anatomy and Histology (Second Edition), Academic Press, San Diego, 2018: pp. 445\u2013470. https:\/\/doi.org\/10.1016\/B978-0-12-802900-8.00021-X.","DOI":"10.1016\/B978-0-12-802900-8.00021-X"},{"key":"10.1016\/j.addr.2022.114342_b0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0235","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.preteyeres.2010.04.001","article-title":"Protein delivery for retinal diseases: From basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0240","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0245","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and Lipophilicity","volume":"46","author":"Pitk\u00e4nen","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/ijms21010211","article-title":"Tight Junctions of the Outer Blood Retina Barrier","volume":"21","author":"Naylor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0255","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1389200043335342","article-title":"Role of metabolism in ocular drug delivery","volume":"5","author":"Duvvuri","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2022.114342_b0260","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0265","first-page":"339","article-title":"Rheology of the vitreous body: part 3 Concentration of electrolytes, collagen and hyaluronic acid","volume":"31","author":"Lee","year":"1994","journal-title":"Biorheology"},{"key":"10.1016\/j.addr.2022.114342_b0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.survophthal.2014.07.002","article-title":"Misdirected aqueous flow in rhegmatogenous retinal detachment: A pathophysiology update","volume":"60","author":"Tabibian","year":"2015","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114342_b0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0285","first-page":"165","article-title":"The Vitreous, the Retinal Interface in Ocular Health and Disease","volume":"230","author":"de Smet","year":"2013","journal-title":"OPH."},{"key":"10.1016\/j.addr.2022.114342_b0290","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and Composition of the Inner Limiting Membrane: Species-Specific Variations and Relevance toward Drug Delivery Research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0295","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.biomaterials.2012.01.030","article-title":"The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection","volume":"33","author":"Koo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0300","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly(lactic-co-glycolic acid) microparticles","volume":"17","author":"van de Weert","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.addr.2022.114342_b0310","doi-asserted-by":"crossref","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2022.114342_b0315","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1167\/iovs.04-0091","article-title":"Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging","volume":"45","author":"Kim","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0320","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/21691401.2018.1478845","article-title":"Polymeric, injectable, intravitreal hydrogel devices for posterior segment applications and interventions","volume":"46","author":"Anwary","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.addr.2022.114342_b0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","article-title":"Intravitreal dexamethasone implant Ozurdex\u00ae in na\u00efve and refractory patients with different subtypes of diabetic macular edema","volume":"19","author":"Castro-Navarro","year":"2019","journal-title":"BMC Ophthalmology."},{"key":"10.1016\/j.addr.2022.114342_b0330","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/1080768041223611","article-title":"Ocular Pharmacokinetics of Fluocinolone Acetonide After RetisertTM Intravitreal Implantation in Rabbits Over a 1-Year Period","volume":"20","author":"Driot","year":"2004","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114342_b0335","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14740338.2015.1041916","article-title":"Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation","volume":"14","author":"Sadiq","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.addr.2022.114342_b0340","first-page":"317","article-title":"Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis","volume":"6","author":"Haghjou","year":"2011","journal-title":"J. Ophthalmic. Vis. Res."},{"key":"10.1016\/j.addr.2022.114342_b0345","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien: a new sustained delivery technology for posterior eye disease","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0350","first-page":"350","article-title":"Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0355","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/OPTH.S194234","article-title":"Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date","volume":"14","author":"Chen","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0360","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable Implants for Sustained Drug Release in the Eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0365","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0370","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/eye.2013.287","article-title":"Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1)","volume":"28","author":"Mathew","year":"2014","journal-title":"Eye."},{"key":"10.1016\/j.addr.2022.114342_b0375","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ejpb.2007.08.004","article-title":"Dexamethasone-loaded poly(\u03b5-caprolactone) intravitreal implants: A pilot study","volume":"68","author":"Fialho","year":"2008","journal-title":"European J. Pharmaceutics Biopharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0380","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1167\/iovs.08-2969","article-title":"Poly-\u03b5-Caprolactone Intravitreous Devices: An In Vivo Study","volume":"50","author":"Silva-Cunha","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0385","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1021\/nl302747y","article-title":"Nanostructured Thin Film Polymer Devices for Constant-Rate Protein Delivery","volume":"12","author":"Bernards","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2022.114342_b0390","unstructured":"ILUVIEN, Summary of Product Characteristics, https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA22620-001-001_24092021112540.pdf."},{"key":"10.1016\/j.addr.2022.114342_b0395","doi-asserted-by":"crossref","unstructured":"K.B. Ryan, S. Maher, D.J. Brayden, C.M. O\u2019driscoll, Chapter 2.2: NANOSTRUCTURES OVERCOMING THE INTESTINAL BARRIER: DRUG DELIVERY STRATEGIES, in: Nanostructured Biomaterials for Overcoming Biological Barriers, 2012: pp. 63\u201390. https:\/\/doi.org\/10.1039\/9781849735292-00063.","DOI":"10.1039\/9781849735292-00063"},{"key":"10.1016\/j.addr.2022.114342_b0400","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","article-title":"Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants","volume":"103","author":"Sieving","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2022.114342_b0405","first-page":"3292","article-title":"Encapsulated Cell-Based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa","volume":"43","author":"Tao","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0410","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups, Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0415","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent advances in ophthalmic drug delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0420","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9394(98)00443-7","article-title":"Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis","volume":"127","author":"Lim","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0425","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/19420862.2017.1372078","article-title":"Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye","volume":"9","author":"Tesar","year":"2017","journal-title":"MAbs."},{"key":"10.1016\/j.addr.2022.114342_b0430","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2009.10.031","article-title":"Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats","volume":"142","author":"Kim","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0435","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1167\/iovs.10-5676","article-title":"Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis","volume":"52","author":"Sakai","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0440","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2019.01.012","article-title":"Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma","volume":"297","author":"Arranz-Romera","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0445","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1208\/s12249-020-01836-4","article-title":"Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration","volume":"21","author":"Bhatt","year":"2020","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.addr.2022.114342_b0450","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.actbio.2019.07.054","article-title":"Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization","volume":"97","author":"Kim","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2022.114342_b0455","doi-asserted-by":"crossref","first-page":"E706","DOI":"10.3390\/pharmaceutics12080706","article-title":"Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy","volume":"12","author":"Mietzner","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0460","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.01.036","article-title":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","volume":"320","author":"Jiang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0465","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.2147\/IJN.S108452","article-title":"Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage","volume":"11","author":"Jeong","year":"2016","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2022.114342_b0470","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1167\/iovs.15-16538","article-title":"Neuroprotective Effects of Human Serum Albumin Nanoparticles Loaded With Brimonidine on Retinal Ganglion Cells in Optic Nerve Crush Model","volume":"56","author":"Kim","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0475","first-page":"1","article-title":"Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats","volume":"7","author":"Lu","year":"2014","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2012.09.010","article-title":"Low molecular weight oligochitosans for non-viral retinal gene therapy","volume":"83","author":"Puras","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114342_b0485","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","article-title":"Methods for preparation of drug-loaded polymeric nanoparticles","volume":"2","author":"Pinto Reis","year":"2006","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.addr.2022.114342_b0490","first-page":"39","article-title":"Biodegradable polymers in controlled drug delivery","volume":"1","author":"Heller","year":"1984","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.addr.2022.114342_b0495","series-title":"Treatise on Ocular Drug Delivery","first-page":"114","author":"Thakur","year":"2013"},{"key":"10.1016\/j.addr.2022.114342_b0500","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.addr.2018.03.013","article-title":"Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges","volume":"126","author":"Lau","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114342_b0505","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.molpharmaceut.6b00335","article-title":"PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab","volume":"13","author":"Elsaid","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114342_b0510","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exer.2014.11.002","article-title":"Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide","volume":"129","author":"Wang","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0515","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.2147\/IJN.S217038","article-title":"Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications","volume":"14","author":"Liu","year":"2019","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.addr.2022.114342_b0520","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114342_b0525","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"issue":"30","key":"10.1016\/j.addr.2022.114342_b0530","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.biomaterials.2013.06.044","article-title":"Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide","volume":"34","author":"Shmueli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0535","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2018.03.034","article-title":"Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia","volume":"168","author":"Huang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/108076801753162807","article-title":"Review: Practical Issues in Intravitreal Drug Delivery","volume":"4","author":"Maurice","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114342_b0545","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1167\/iovs.12-11460","article-title":"Different Intravitreal Properties of Three Triamcinolone Formulations and Their Possible Impact on Retina Practice","volume":"54","author":"Chen","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0550","doi-asserted-by":"crossref","unstructured":"T. Yasukawa, Y. Ogura, Medical Devices for the Treatment of Eye Diseases, in: M. Sch\u00e4fer-Korting (Ed.), Drug Delivery, Springer, Berlin, Heidelberg, 2010: pp. 469\u2013489. https:\/\/doi.org\/10.1007\/978-3-642-00477-3_16.","DOI":"10.1007\/978-3-642-00477-3_16"},{"key":"10.1016\/j.addr.2022.114342_b0555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0560","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.addr.2022.114342_b0565","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.6.20","article-title":"Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Vis Sci Technol."},{"key":"10.1016\/j.addr.2022.114342_b0570","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1080\/10717544.2017.1375578","article-title":"Toward smart design of retinal drug carriers: a novel bovine retinal explant model to study the barrier role of the vitreoretinal interface","volume":"24","author":"Peynshaert","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0575","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bpj.2015.10.002","article-title":"Diffusion Regulation in the Vitreous Humor","volume":"109","author":"K\u00e4sdorf","year":"2015","journal-title":"Biophys. J ."},{"key":"10.1016\/j.addr.2022.114342_b0580","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107711","article-title":"Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles","volume":"186","author":"Huang","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0590","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s11671-018-2457-x","article-title":"Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties","volume":"13","author":"Sukhanova","year":"2018","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.addr.2022.114342_b0595","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2015.01.030","article-title":"Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy","volume":"202","author":"Martens","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114342_b0600","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1167\/iovs.08-3044","article-title":"Involvement of Hyaluronan and Its Receptor CD44 with Choroidal Neovascularization","volume":"50","author":"Mochimaru","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0605","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1167\/iovs.05-0165","article-title":"Vitreous: A Barrier to Nonviral Ocular Gene Therapy","volume":"46","author":"Peeters","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0610","first-page":"1","article-title":"Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules, Transl Vis","volume":"8","author":"Crowell","year":"2019","journal-title":"Sci Technol."},{"key":"10.1016\/j.addr.2022.114342_b0615","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1021\/acs.molpharmaceut.6b00345","article-title":"Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab","volume":"13","author":"Shatz","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114342_b0620","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1442-9071.2011.02651.x","article-title":"Investigation of nanoparticles using magnetic resonance imaging after intravitreal injection","volume":"40","author":"Raju","year":"2012","journal-title":"Clin Exp Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0625","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"10.1016\/j.addr.2022.114342_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017452","article-title":"Evaluation of Magnetic Micro- and Nanoparticle Toxicity to Ocular Tissues","volume":"6","author":"Raju","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114342_b0635","first-page":"3","volume":"2","author":"Zhou","year":"2010","journal-title":"Ocular immune privilege, F1000 Biol Rep."},{"key":"10.1016\/j.addr.2022.114342_b0640","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.it.2015.04.003","article-title":"Immune Mechanisms in Inflammatory and Degenerative Eye Disease","volume":"36","author":"Perez","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2022.114342_b0645","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/nano5031351","article-title":"Role of Physicochemical Properties in Nanoparticle Toxicity","volume":"5","author":"Shin","year":"2015","journal-title":"Nanomaterials."},{"key":"10.1016\/j.addr.2022.114342_b0650","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1167\/iovs.16-21334","article-title":"Evaluation of the Toxicity of Intravitreally Injected PLGA Microspheres and Rods in Monkeys and Rabbits: Effects of Depot Size on Inflammatory Response","volume":"58","author":"Thackaberry","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0655","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11095-008-9626-z","article-title":"Shape Induced Inhibition of Phagocytosis of Polymer Particles","volume":"26","author":"Champion","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0660","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biomaterials.2017.02.006","article-title":"Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats","volume":"124","author":"Peters","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0665","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0192623320948851","article-title":"Foreign Body Reaction, Retinal Degeneration, and Epiretinal Membranes Associated With Intravitreal Administration of PLGA Rods","volume":"49","author":"Booler","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2022.114342_b0670","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/17425247.2015.1003807","article-title":"Production methods and stabilization strategies for polymer-based nanoparticles and microparticles for parenteral delivery of peptides and proteins","volume":"12","author":"Teekamp","year":"2015","journal-title":"Expert Opinion on Drug Delivery."},{"key":"10.1016\/j.addr.2022.114342_b0675","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/17425240903199143","article-title":"Recent trends in stabilising peptides and proteins in pharmaceutical formulation \u2013 considerations in the choice of excipients","volume":"6","author":"Jorgensen","year":"2009","journal-title":"Expert Opinion on Drug Delivery."},{"issue":"3","key":"10.1016\/j.addr.2022.114342_b0680","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114342_b0685","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/jps.21176","article-title":"Chemical Degradation of Peptides and Proteins in PLGA: A Review of Reactions and Mechanisms","volume":"97","author":"Houchin","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0690","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1023\/A:1011009117586","article-title":"Stabilization and controlled release of bovine serum albumin encapsulated in poly(D, L-lactide) and poly(ethylene glycol) microsphere blends","volume":"18","author":"Jiang","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0695","series-title":"Biomedical Applications of Nanoparticles","first-page":"163","article-title":"Chapter 7 - Synthesis of hydrogels and their emerging role in pharmaceutics","author":"Yasin","year":"2019"},{"key":"10.1016\/j.addr.2022.114342_b0700","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2022.114342_b0705","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.polymer.2008.01.027","article-title":"Hydrogels in drug delivery: Progress and challenges","volume":"49","author":"Hoare","year":"2008","journal-title":"Polymer"},{"key":"10.1016\/j.addr.2022.114342_b0710","doi-asserted-by":"crossref","unstructured":"R. parhi, Cross-Linked Hydrogel for Pharmaceutical Applications: A Review, Adv Pharm Bull. 7 (2017) 515\u2013530. https:\/\/doi.org\/10.15171\/apb.2017.064.","DOI":"10.15171\/apb.2017.064"},{"key":"10.1016\/j.addr.2022.114342_b0715","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eurpolymj.2014.11.024","article-title":"Biomedical applications of hydrogels: A review of patents and commercial products","volume":"65","author":"Cal\u00f3","year":"2015","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.addr.2022.114342_b0720","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fchem.2018.00499","article-title":"Functional Hydrogels With Tunable Structures and Properties for Tissue Engineering Applications","volume":"6","author":"Li","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2022.114342_b0725","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/polym13040650","article-title":"Injectable Hydrogels: From Laboratory to Industrialization","volume":"13","author":"Alonso","year":"2021","journal-title":"Polymers."},{"key":"10.1016\/j.addr.2022.114342_b0730","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3109\/08820538.2010.541318","article-title":"Intravitreal Injection Technique","volume":"26","author":"Doshi","year":"2011","journal-title":"Seminars in Ophthalmology."},{"key":"10.1016\/j.addr.2022.114342_b0735","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2015.05.071","article-title":"An injectable thermosensitive polymeric hydrogel for sustained release of Avastin\u00ae to treat posterior segment disease","volume":"490","author":"Xie","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114342_b0740","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/10717544.2019.1587042","article-title":"A biocompatible reverse thermoresponsive polymer for ocular drug delivery","volume":"26","author":"Balachandra","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0745","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mabi.201200384","article-title":"An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration","volume":"13","author":"Park","year":"2013","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.addr.2022.114342_b0750","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo","volume":"55","author":"Rauck","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0755","first-page":"206","article-title":"Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye","volume":"106","author":"Kang Derwent","year":"2008","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.addr.2022.114342_b0760","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s11095-013-1195-0","article-title":"The Effect of Glutathione as Chain Transfer Agent in PNIPAAm-Based Thermo-responsive Hydrogels for Controlled Release of Proteins","volume":"31","author":"Drapala","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114342_b0765","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3109\/02713683.2015.1101140","article-title":"Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System","volume":"41","author":"Osswald","year":"2016","journal-title":"Curr. Eye Res."},{"issue":"9","key":"10.1016\/j.addr.2022.114342_b0770","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/02713683.2017.1302590","article-title":"In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System","volume":"42","author":"Osswald","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0775","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.3.30","article-title":"Safety and Biocompatibility of Aflibercept-Loaded Microsphere Thermo-Responsive Hydrogel Drug Delivery System in a Nonhuman Primate Model","volume":"9","author":"Kim","year":"2020","journal-title":"Trans Vis Sci Tech."},{"key":"10.1016\/j.addr.2022.114342_b0780","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/02713683.2018.1533983","article-title":"Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro","volume":"44","author":"Liu","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0785","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/mabi.201400250","article-title":"A Combined Micelle and Poly(Serinol Hexamethylene Urea)-Co-Poly(N-Isopropylacrylamide) Reverse Thermal Gel as an Injectable Ocular Drug Delivery System","volume":"14","author":"Famili","year":"2014","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.addr.2022.114342_b0790","first-page":"2858","article-title":"Light-Activated","volume":"10","author":"Tyagi","year":"2013","journal-title":"In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab, Mol Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0795","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jddst.2017.06.006","article-title":"Preparation and evaluation of PLGA nanoparticle-loaded biodegradable light-responsive injectable implants as a promising platform for intravitreal drug delivery","volume":"40","author":"Bisht","year":"2017","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.addr.2022.114342_b0800","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of avastin\u00ae from polysaccharides cross-linked hydrogels for ocular drug delivery","volume":"60","author":"Xu","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2022.114342_b0805","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2014.04.053","article-title":"In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications","volume":"470","author":"Yu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114342_b0810","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl Vis Sci Technol."},{"issue":"6","key":"10.1016\/j.addr.2022.114342_b0815","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0391398818765323","article-title":"Biopolymer-based strategies in the design of smart medical devices and artificial organs","volume":"41","author":"Altomare","year":"2018","journal-title":"Int. J. Artif. Organs"},{"key":"10.1016\/j.addr.2022.114342_b0820","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1039\/C9TB02052G","article-title":"Thermoresponsive polymers and their biomedical application in tissue engineering \u2013 a review","volume":"8","author":"Doberenz","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2022.114342_b0825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10965-019-1771-z","article-title":"Thermosensitive hydrogel-based drug delivery system for sustained drug release","volume":"26","author":"Patel","year":"2019","journal-title":"J. Polym. Res."},{"issue":"2","key":"10.1016\/j.addr.2022.114342_b0830","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/pharmaceutics13020234","article-title":"Thermo-Responsive PLGA-PEG-PLGA Hydrogels as Novel Injectable Platforms for Neuroprotective Combined Therapies in the Treatment of Retinal Degenerative Diseases","volume":"13","author":"L\u00f3pez-Cano","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b0835","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biomaterials.2010.09.044","article-title":"A functionalizable reverse thermal gel based on a polyurethane\/PEG block copolymer","volume":"32","author":"Park","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0840","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2015.04.032","article-title":"Recent progress in biomedical applications of Pluronic (PF127): Pharmaceutical perspectives","volume":"209","author":"Akash","year":"2015","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2022.114342_b0845","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00006982-199010000-00013","article-title":"OCULAR TOXICITY OF VITREAL PLURONIC POLYOL F-127","volume":"10","author":"Davidorf","year":"1990","journal-title":"RETINA."},{"key":"10.1016\/j.addr.2022.114342_b0850","first-page":"99","article-title":"Studies on thermoresponsive polymers: Phase behaviour, drug delivery and biomedical applications, Asian","volume":"10","author":"Gandhi","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114342_b0855","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1016\/j.biomaterials.2004.09.008","article-title":"Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam)","volume":"26","author":"Vihola","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0860","doi-asserted-by":"crossref","first-page":"5356371","DOI":"10.1155\/2016\/5356371","article-title":"Ocular Biocompatibility of Poly-N-Isopropylacrylamide (pNIPAM)","volume":"2016","author":"Lima","year":"2016","journal-title":"J Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b0865","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.drudis.2019.05.037","article-title":"Hydrogels for sustained delivery of biologics to the back of the eye","volume":"24","author":"Chang","year":"2019","journal-title":"Drug Discov Today."},{"issue":"4","key":"10.1016\/j.addr.2022.114342_b0870","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114342_b0875","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/IAE.0b013e3182647f69","article-title":"ASSESSMENT OF THE DIFFERENCES IN PHARMACOKINETICS AND PHARMACODYNAMICS BETWEEN FOUR DISTINCT FORMULATIONS OF TRIAMCINOLONE ACETONIDE","volume":"33","author":"Zacharias","year":"2013","journal-title":"RETINA."},{"key":"10.1016\/j.addr.2022.114342_b0880","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/17425247.2016.1163334","article-title":"Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye","volume":"13","author":"Bisht","year":"2016","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2022.114342_b0885","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.drudis.2007.12.005","article-title":"Ophthalmic light sensitive nanocarrier systems","volume":"13","author":"Christie","year":"2008","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.addr.2022.114342_b0890","doi-asserted-by":"crossref","unstructured":"L. Amselem, J.M. Mon\u00e9s, L. Arias, CHAPTER 43 - Photosensitizers and photodynamic therapy: verteporfin, in: Q.D. Nguyen, E.B. Rodrigues, M.E. Farah, W.F. Mieler (Eds.), Retinal Pharmacotherapy, W.B. Saunders, Edinburgh, 2010: pp. 297\u2013305. https:\/\/doi.org\/10.1016\/B978-1-4377-0603-1.00048-X.","DOI":"10.1016\/B978-1-4377-0603-1.00048-X"},{"key":"10.1016\/j.addr.2022.114342_b0895","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1039\/b705619b","article-title":"Photo-mechanical effects in azobenzene-containing soft materials","volume":"3","author":"Barrett","year":"2007","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2022.114342_b0900","series-title":"Drug Targeting and Stimuli Sensitive Drug Delivery Systems","first-page":"303","article-title":"Chapter 8 - Stimuli-responsive micelles: A nanoplatform for therapeutic and diagnostic applications","author":"Nair","year":"2018"},{"key":"10.1016\/j.addr.2022.114342_b0905","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1039\/c3cc43488e","article-title":"Macroscopic motion of supramolecular assemblies actuated by photoisomerization of azobenzene derivatives","volume":"49","author":"Kageyama","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2022.114342_b0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mser.2015.04.001","article-title":"Stimulus-responsive hydrogels: Theory, modern advances, and applications","volume":"93","author":"Koetting","year":"2015","journal-title":"Mater. Sci. Eng. R Rep."},{"key":"10.1016\/j.addr.2022.114342_b0915","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cptc.201700233","article-title":"Photoswitchable Azobenzene\/Cyclodextrin Host-Guest Complexes: From UV- to Visible\/Near-IR-Light-Responsive Systems","volume":"2","author":"Wang","year":"2018","journal-title":"ChemPhotoChem."},{"key":"10.1016\/j.addr.2022.114342_b0920","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1039\/c002565h","article-title":"Light controlled protein release from a supramolecular hydrogel","volume":"46","author":"Peng","year":"2010","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2022.114342_b0925","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1039\/b006013p","article-title":"Photodimerization of anthracenes in fluid solutions: (part 2) mechanistic aspects of the photocycloaddition and of the photochemical and thermal cleavage","volume":"30","author":"Bouas-Laurent","year":"2001","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2022.114342_b0930","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/bm101233m","article-title":"Photoresponsive PEG-Anthracene Grafted Hyaluronan as a Controlled-Delivery Biomaterial","volume":"12","author":"Wells","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2022.114342_b0935","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/mabi.201100001","article-title":"Generic, anthracene-based hydrogel crosslinkers for photo-controllable drug delivery","volume":"11","author":"Wells","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.addr.2022.114342_b0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/9208489","article-title":"Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone)","volume":"2017","author":"Masuda","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"10.1016\/j.addr.2022.114342_b0945","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exer.2010.04.002","article-title":"Mechanisms of retinal ganglion cell injury and defense in glaucoma","volume":"91","author":"Qu","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114342_b0950","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.biomaterials.2015.08.045","article-title":"Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels","volume":"73","author":"Yue","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0955","first-page":"1799","article-title":"Design and fabrication of GelMA\/chitosan nanoparticles composite hydrogel for angiogenic growth factor delivery","volume":"46","author":"Modaresifar","year":"2018","journal-title":"Artif Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.addr.2022.114342_b0960","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.biomaterials.2009.01.034","article-title":"Photocrosslinked alginate hydrogels with tunable biodegradation rates and mechanical properties","volume":"30","author":"Jeon","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0965","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/86684","article-title":"A clearer vision for in vivo imaging","volume":"19","author":"Weissleder","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114342_b0970","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1021\/bc200281k","article-title":"Regenerative Biomaterials that \u201cClick\u201d: Simple, Aqueous-Based Protocols for Hydrogel Synthesis, Surface Immobilization, and 3D Patterning","volume":"22","author":"Nimmo","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2022.114342_b0975","doi-asserted-by":"crossref","first-page":"E3005","DOI":"10.3390\/molecules24163005","article-title":"Hydrogels Based on Schiff Base Linkages for Biomedical Applications","volume":"24","author":"Xu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2022.114342_b0980","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s10856-012-4757-5","article-title":"A covalently crosslinked polysaccharide hydrogel for potential applications in drug delivery and tissue engineering","volume":"23","author":"Li","year":"2012","journal-title":"J. Mater. Sci. - Mater. Med."},{"key":"10.1016\/j.addr.2022.114342_b0985","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acsbiomaterials.5b00420","article-title":"Thiol\u2013ene Click Hydrogels for Therapeutic Delivery","volume":"2","author":"Kharkar","year":"2016","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.addr.2022.114342_b0990","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1016\/j.biomaterials.2014.03.001","article-title":"Click hydrogels, microgels and nanogels: Emerging platforms for drug delivery and tissue engineering","volume":"35","author":"Jiang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b0995","article-title":"Drug release from hydrogel matrices","volume":"17","author":"Zarzycki","year":"2010","journal-title":"Ecol. Chem. Eng. S"},{"key":"10.1016\/j.addr.2022.114342_b1000","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2019.01.076","article-title":"An overview on the mathematical modeling of hydrogels\u2019 behavior for drug delivery systems","volume":"560","author":"Caccavo","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114342_b1005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.addr.2006.09.004","article-title":"Hydrogels in controlled release formulations: Network design and mathematical modeling","volume":"58","author":"Lin","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114342_b1010","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/pharmaceutics12121188","article-title":"Hydrogels as Drug Delivery Systems: A Review of Current Characterization and Evaluation Techniques","volume":"12","author":"Vigata","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114342_b1015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0142-9612(96)85755-3","article-title":"Mechanisms of polymer degradation and erosion","volume":"17","author":"G\u00f6pferich","year":"1996","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b1020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(01)00116-8","article-title":"Mathematical modeling of bioerodible, polymeric drug delivery systems","volume":"48","author":"Siepmann","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114342_b1025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.addr.2022.114342_b1030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114342_b1035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biomaterials.2011.10.010","article-title":"Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration","volume":"33","author":"Iezzi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114342_b1040","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jphp.12587","article-title":"Dexamethasone \u2013 PAMAM dendrimer conjugates for retinal delivery: preparation, characterization and in vivo evaluation","volume":"68","author":"Yavuz","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114342_b1045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejpb.2015.02.013","article-title":"Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells","volume":"95","author":"Kambhampati","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114342_b1050","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/sj.gt.3302579","article-title":"Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity","volume":"12","author":"Marano","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2022.114342_b1055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The Impact of PEGylation on Biological Therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs."},{"key":"10.1016\/j.addr.2022.114342_b1060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1021\/cm2031569","article-title":"Polymeric conjugates for drug delivery","volume":"24","author":"Larson","year":"2012","journal-title":"Chem. Mater."},{"key":"10.1016\/j.addr.2022.114342_b1065","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2032-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165): inhibition of receptor binding and vegf-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114342_b1070","first-page":"244","article-title":"Pegylation of Abicipar Increases Vitreal Half-Life, Supporting a Potential for up to 3 Month Duration of Action in the Clinic","volume":"59","author":"Seal","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b1075","article-title":"KSI-301: antibody biopolymer conjugate in retinal disorders","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Ther Adv Ophthalmol."},{"key":"10.1016\/j.addr.2022.114342_b1080","doi-asserted-by":"crossref","unstructured":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases, EMBO Mol Med. 8 (2016) 1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889.","DOI":"10.15252\/emmm.201505889"},{"key":"10.1016\/j.addr.2022.114342_b1085","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1167\/iovs.18-25307","article-title":"Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability","volume":"59","author":"Rodrigues","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b1090","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41433-019-0584-y","article-title":"Abicipar pegol\u2014a novel anti-VEGF therapy with a long duration of action","volume":"34","author":"Moisseiev","year":"2020","journal-title":"Eye."},{"key":"10.1016\/j.addr.2022.114342_b1095","first-page":"1968","article-title":"Efficacy of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in a VEGF Induced Retinal Leakage Model","volume":"58","author":"Elhayek","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b1100","unstructured":"OTX-TKI (axitinib intravitreal implant) \u2013 Ocular Therapeutix. https:\/\/www.ocutx.com\/research\/otx-tki\/."},{"key":"10.1016\/j.addr.2022.114342_b1105","first-page":"5037","article-title":"GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE\/Choroid for Over Four Months","volume":"57","author":"Yang","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114342_b1110","unstructured":"Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration, Graybug. (2019). https:\/\/www.graybug.vision\/graybug-vision-initiates-phase-2b-altissimo-clinical-trial-of-gb-102-in-patients-with-wet-age-related-macular-degeneration\/."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22002320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22002320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:20:56Z","timestamp":1759209656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":222,"alternative-id":["S0169409X22002320"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114342","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114342"}}